FinancingHeidelberg-based Veraxa ventures onto Nasdaq in turbulent market environmentVeraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading … more ➔
ResearchScenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’sScenic Biotech has joined the Michael J. Fox Foundation’s LRRK2 consortium to test a Parkinson’s disease approach that targets neither LRRK2 nor GCase directly. more ➔
clinical dataSanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into troubleSanofi’s $11.6bn Bioverativ acquisition is back under scrutiny after riliprubart, a rare disease drug inherited through the deal, failed a phase 3 CIDP study. While Altuviiio has become a blockbuster, … more ➔
fundraisingCircio completes NOK300m financing to fund circular RNA platform developmentOslo-based Circio has completed a NOK300m (€27m) financing round, extending its runway to the end of 2030 and giving the company funds to advance its circVec circular RNA expression platform toward … more ➔
licensingAlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bnSwedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under … more ➔
obesityBoehringer/Zealand obesity drug delivers Phase III weight loss, but side effects raise questionsBoehringer Ingelheim has reported new Phase III data for survodutide, its once-weekly dual GLP-1/glucagon receptor agonist for obesity, highlighting reductions in body weight, visceral fat and liver … more ➔
clinical dataBial drops pariceract after Phase IIb failure in GBA-associated Parkinson’sPortuguese drugmaker BIAL has discontinued development of BIA 28-6156, also known as pariceract, after a Phase IIb study failed to show that the oral therapy could slow progression in patients with GBA-associated … more ➔
EngitixlicensingGSK taps Engitix’s platform in liver fibrosis deal worth up to £44.5m upfrontLondon-based Engitix Ltd has entered a strategic research collaboration and option agreement with GSK to discover and validate new therapeutic targets for liver fibrosis regression, adding another pharma … more ➔
licensingRoche bets on BTK degradation in $2.3bn Nurix dealSwiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase … more ➔
clinical dataADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control armSwiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events … more ➔
Engitix
